Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review.

ABSTRACT:

Purpose of the review

Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are recommended for eligible patients with type 2 diabetes for the secondary prevention of adverse cardiovascular and kidney disease outcomes. Patients with type 2 diabetes and albuminuric chronic kidney disease, a history of atherosclerotic cardiovascular disease, and/or heart failure with reduced ejection fraction should be assessed for the use of these therapies.

Sources of information

The sources include published clinical trials with SGLT2is, with a focus on cardiovascular safety studies and kidney protection trials.

Methods

Information was gathered via a review of relevant literature and clinical practice guidelines, incorporated with real-life clinical experience.

Key findings

Clin

SUBMITTER: Dubrofsky L 

PROVIDER: S-EPMC7315675 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature